MA58653A1 - USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO ABERRANT INTERLEUKIN-6 ACTIVITY - Google Patents

USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO ABERRANT INTERLEUKIN-6 ACTIVITY

Info

Publication number
MA58653A1
MA58653A1 MA58653A MA58653A MA58653A1 MA 58653 A1 MA58653 A1 MA 58653A1 MA 58653 A MA58653 A MA 58653A MA 58653 A MA58653 A MA 58653A MA 58653 A1 MA58653 A1 MA 58653A1
Authority
MA
Morocco
Prior art keywords
activity
aberrant
interleukin
diseases related
treat diseases
Prior art date
Application number
MA58653A
Other languages
French (fr)
Other versions
MA58653B1 (en
Inventor
Vladimir Evgenievich Nebolsin
Original Assignee
Valenta Intellekt Ltd
Vladimir Evgenievich Nebolsin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2020121363A external-priority patent/RU2774928C2/en
Application filed by Valenta Intellekt Ltd, Vladimir Evgenievich Nebolsin filed Critical Valenta Intellekt Ltd
Publication of MA58653A1 publication Critical patent/MA58653A1/en
Publication of MA58653B1 publication Critical patent/MA58653B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention se rapporte au domaine de la médecine et concerne un traitement de maladies associées à une activité aberrante l'interleukine-6 et au développement du syndrome de libération de cytokines (choc cytokinique), de préférence un traitement du covid-19, ainsi que d'autres maladies compliquées par une activité aberrante d'interleukine-6 et le développement d'un syndrome de libération de cytokines, ceci en utilisant un composé de 1-(2-(1-méthyl-1?-imidazol-4- yl)éthyl)pipéridine-2,6-dione (i). L'invention permet de créer un nouvel agent médicamenteux efficace pour le traitement de maladies associées au développement du syndrome de libération de cytokines.The present invention relates to the field of medicine and relates to treatment of diseases associated with aberrant interleukin-6 activity and the development of cytokine release syndrome (cytokine shock), preferably treatment of covid-19, as well as other diseases complicated by aberrant interleukin-6 activity and the development of cytokine release syndrome, using a 1-(2-(1-methyl-1?-imidazol-4- yl)ethyl)piperidine-2,6-dione (i). The invention makes it possible to create a new medicinal agent effective for the treatment of diseases associated with the development of cytokine release syndrome.

MA58653A 2020-06-26 2021-06-18 USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO ABERRANT INTERLEUKIN-6 ACTIVITY MA58653B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2020121363A RU2774928C2 (en) 2020-06-26 Use of glutarimide derivative for therapy of diseases associated with aberrant activity of interleukin-6
PCT/RU2021/050170 WO2021262040A1 (en) 2020-06-26 2021-06-18 Use of a glutarimide derivative for treating diseases associated with aberrant interleukin-6 activity

Publications (2)

Publication Number Publication Date
MA58653A1 true MA58653A1 (en) 2023-07-31
MA58653B1 MA58653B1 (en) 2024-02-29

Family

ID=79281595

Family Applications (1)

Application Number Title Priority Date Filing Date
MA58653A MA58653B1 (en) 2020-06-26 2021-06-18 USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO ABERRANT INTERLEUKIN-6 ACTIVITY

Country Status (6)

Country Link
CN (1) CN115803026A (en)
BR (1) BR112022026356A2 (en)
CL (1) CL2022003725A1 (en)
CO (1) CO2023000604A2 (en)
MA (1) MA58653B1 (en)
WO (1) WO2021262040A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023177329A1 (en) * 2022-03-18 2023-09-21 Общество С Ограниченной Ответственностью "Валента-Интеллект" Use of 1-(2-(1н-imidazole-4-yl)ethyl)piperidine-2,6-dione to treat cough caused by viral infections
WO2023249516A1 (en) * 2022-06-24 2023-12-28 Общество С Ограниченной Ответственностью "Валента-Интеллект" Novel crystalline form of 1-[2-(1-methylimidazole-4-yl)ethyl]perhydroazine-2,6-dione and pharmaceutical use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2112716A1 (en) * 1971-03-17 1972-10-05 Thomae Gmbh Dr K Biphenylyl-butyric acid derivs. - anti phlogistics
DE10002509A1 (en) * 2000-01-21 2001-07-26 Gruenenthal Gmbh New substituted glutarimide derivatives are IL-12 antagonists, are useful as immunomodulators and for the treatment of angiopathy, hematological or oncological disorders
UA115431C2 (en) * 2011-10-11 2017-11-10 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Use of glutaryl histamine to treat respiratory tract infections
CN102432544B (en) * 2011-11-17 2014-05-21 天津医科大学 5-substituted benzyl methylene imidazole alkyl-2,4-diketone derivative and application thereof
BR122020010204B1 (en) * 2013-04-12 2022-03-03 Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" COMPOUND DERIVED FROM GLUTARIMIDE, ITS USE, PHARMACEUTICAL COMPOSITION AND METHOD OF PREPARATION
RU2552929C1 (en) * 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Pharmaceutical composition, containing derivatives of glutarimides, and their application for treatment of eosinophilic diseases
US10739353B2 (en) * 2014-12-31 2020-08-11 Signpath Pharma, Inc. Suppression of cytokine release and cytokine storm
GEP20227354B (en) * 2017-09-07 2022-02-25 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines
JP2023522618A (en) * 2020-04-13 2023-05-31 ユニバーシティー ヘルス ネットワーク Methods for treating cytokine release syndrome
EP4144728A4 (en) * 2020-04-30 2023-08-23 Shanghaitech University Heterocycle and glutarimide skeleton-based compound and applications thereof

Also Published As

Publication number Publication date
CL2022003725A1 (en) 2023-05-19
RU2020121363A (en) 2021-12-27
CO2023000604A2 (en) 2023-01-26
BR112022026356A2 (en) 2023-01-17
CN115803026A (en) 2023-03-14
MA58653B1 (en) 2024-02-29
WO2021262040A1 (en) 2021-12-30
RU2020121363A3 (en) 2021-12-27

Similar Documents

Publication Publication Date Title
MA58653B1 (en) USE OF A GLUTARIMIDE DERIVATIVE TO TREAT DISEASES RELATED TO ABERRANT INTERLEUKIN-6 ACTIVITY
EA202090955A1 (en) METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS
MA41496B1 (en) Pharmaceutical compositions comprising n- (3,5-dimethoxyphenyl) -n '- (1-methylethyl) -n- [3- (1-methyl-1h-pyrazol-4-yl) quinoxalin-6-yl] ethane-1, 2-diamine
DE60318891D1 (en) CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS
DE60323133D1 (en) CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS
NO20025601D0 (en) Arylmethylamine derivatives for use as tryptase inhibitors
MA40814A1 (en) Pharmaceutical compositions for combination therapy
CR7882A (en) Compounds 2- (1H-Indazol-6-ylamino-benzamides as protein kinase inhibitors useful for the treatment of ophthalmic diseases
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
EP2329842A3 (en) Interleukin-1 inhibitors in the treatment of diseases
TNSN07063A1 (en) THERAPEUTIC USES OF RTP801 INHIBITORS
MA51627B1 (en) Benzofuran, benzopyrrole, substituted benzothiophene and structurally related complement inhibitors
MA28435B1 (en) INDAZOLE CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS
MA30324B1 (en) BENZIMIDAZOLES WITH ACTIVITY AT THE M1 RECEPTOR AND THEIR USE IN MEDICINE
MXPA04001187A (en) Interleukin-1 receptors in the treatment of diseases.
PE20050389A1 (en) QUINOLINE AND QUINOXALINE COMPOUNDS
EA200600480A1 (en) IMIDAZOPIRIDIN-SUBSTITUTE TROPANE DERIVATIVES, possessing the activity of the antagonist CCR5 Receptor, for the treatment of the human immunodeficiency virus (HIV) and inflammation
MY172303A (en) Compositions and methods of use of phorbol esters
CL2004000366A1 (en) USE OF A COMBINATION OF A QUINASA P38 INHIBITING DERIVED COMPOUND OF PIRAZOL, AND AN ACE INHIBITOR TO TREAT RENAL DYSFUNCTION, CARDIOVASCULAR AND VASCULAR DISEASE, RETINOPATHY, NEUROPATIA, EDOTEL, INSOTUNATIO OPINION.
EA200200591A1 (en) PYRROLIDINES THAT INHIBIT CAMP-SPECIFIC PDE
MA47736B1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
EA200201276A1 (en) ARYLMETYLAMINE DERIVATIVES FOR USE AS TRIPTASE INHIBITORS
Machado Andrade et al. Host and viral factors influencing interplay between the macrophage and HIV-1
EA202191150A1 (en) AMINOPEPTIDASE A INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EA202190398A1 (en) CONDENSED RING DERIVATIVE USED AS FGFR4 INHIBITOR